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Abstract— Magnetic resonance imaging (MRI) provides
high resolution brain morphological information and is
used as a biomarker in neurodegenerative diseases. Pop-
ulation studies of brain morphology often seek to identify
pathological structural changes related to different diag-
nostic categories (e.g: controls, mild cognitive impairment
or dementia) which normally describe highly heteroge-
neous groups with a single categorical variable. Instead,
multiple biomarkers are used as a proxy for pathology
and are more powerful in capturing structural variability.
Hence, using the joint modeling of brain morphology and
biomarkers, we aim at describing structural changes re-
lated to any brain condition by means of few underlying
processes. In this regard, we use a multivariate approach
based on Projection to Latent Structures in its regression
variant (PLSR) to study structural changes related to aging
and AD pathology. MRI volumetric and cortical thickness
measurements are used for brain morphology and cere-
brospinal fluid (CSF) biomarkers (t-tau, p-tau and amyloid-
beta) are used as a proxy for AD pathology. By relating
both sets of measurements, PLSR finds a low-dimensional
latent space describing AD pathological effects on brain
structure. The proposed framework allows to separately
model aging effects on brain morphology as a confounder
variable orthogonal to the pathological effect. The predic-
tive power of the associated latent spaces (i.e. the capacity
of predicting biomarker values) is assessed in a cross-
validation framework.
Index Terms— Latent model, PLS, preclinical AD, CSF
biomarkers, MRI
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HUMAN brains are constantly evolving throughout life,changing their neurobiological structure according to
an uncountable number of factors ranging from genetics
or hormonal to vascular factors [?]. Hence, we can define
multiple interdependent processes occurring at the same time
in each subject’s brain. A normal aging process describe
similar changes in groups of subjects with similar age and
can be characterized by subject’s real age. Often, in elderly
subjects, other processes related to dementia occur in parallel
and eventually result in cognitive or memory decline. The
etiology of those processes is still unknown but a large
literature of promising research is being published, specially
for the Alzheimer’s disease (AD), the most common type of
dementia. The work in [?] goes through several examples of
recent findings commenting the evidences found. In that sense,
cerebrospinal fluid (CSF) biomarkers, as a proxy measure of
pathophysiological (Aβ and tau deposition) processes, show
an acceptable sensitivity and specificity for AD diagnostic
purposes and can be used as a measure of disease progression
along the AD continuum [?]. This lead to the definition of the
preclinical (PC) stage of AD, where subjects present abnormal
levels of Aβ in the brain without cognitive decline or clinical
symptoms [?]. More recently, an alternative approach defining
AD as a biological continuum rather than a syndrome has been
proposed [?]. In this line, promising developments in PET
imaging could provide us with more sensitive and specific
pathological biomarkers [?]. On the other hand, high-field
MR imaging provide detailed brain anatomical information
as a measure of brain structure that can be used to study
neurodegenerative processes associated with brain develop-
ment and aging [?], cognitive decline [?], [?] and amyloid
positivity [?]. The inter-relationship between AD pathological
markers, neurodegeneration and cognition is highly studied in
the literature [?], [?]. However, CSF and PET are costly and/or
invasive biomarkers while structural MRI is a cheap and non-
invasive biomarker of neurodegeneration. Hence, the overall
goal of this work is to predict CSF biomarkers using MRI
features and study their relationship. To this end, we consider
two separate processes governing brain morphology along the
AD continuum: aging and AD, measured through age and
CSF biomarkers, respectively. We acknowledge the presence
of other processes (e.g: non-AD pathologies) specially in later
stages of the disease, but these analyses are out of the scope
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of this work.
Structural brain changes are heterogeneous among subjects
[?] and may not be uniform across the brain, specially if re-
lated to dementia. However, we hypothesize that these changes
can be described by a small set of interdependent underlying
processes that define common morphological patterns across
all subjects. We build two different latent models to find
specific effects due to brain aging and AD and couple them in
a single brain structure model. Moreover, we constrain both
models to be orthogonal to each other in order to disentangle
aging from disease processes on brain morphology. We inves-
tigate and compare two different modeling approaches of AD
effects: constant along the continuum or separate models for
different stages. Projection to Latent Structures (also known as
Partial Least Squares) is used in its regression form (PLSR) to
jointly model the variation of MRI measurements as predictor
variables and age and CSF biomarkers as response variables.
Finally, we use the learned patterns for predicting age and AD
pathological markers.
Related work: PLS modelling in any of its variants has
been widely used in neuroimaging studies and a good review
of several applications in the field can be found in [?]. As an
example, PLS is used in [?] to jointly model the variation
of genotype and phenotype in Alzheimer’s disease, using
single nucleotide polymorphisms (SNP) and 5 regional brain
volumes as measurements. A white matter integrity analysis
through diffusion tensor imaging (DTI) is analyzed in [?],
where several diffusion parameters (axial diffusivity (AD),
radial diffusivity (RD) and fractional anisotropy (FA)) are used
to study differences in white matter between different AD
stages. In [?], underlying brain morphometric patterns are used
to predict subjects that convert from mild cognitive impaired
(MCI) to AD-dementia with high predictive power. Similar to
our work, the goal in [?] is to find latent spaces related to aging
and disease processes using PLS to model the variability of
brain shape features with age and clinical scores. Here, they
jointly model aging and AD effects using age and the mini
mental score examination (MMSE) cognitive test, respectively.
In a cross-sectional analysis, they find overlap between aging
and AD processes while using longitudinal data disentangles
both effects. Other multivariate methods used for diagnosis
classification using a wide range of imaging modalities are
described in [?]. However, clinical scores or cognitive profiles
(i.e MMSE) are better suited to assess dementia as a syndrome
rather than to characterize the full spectrum of AD. In that
sense, CSF biomarkers are widely used as a proxy fo AD
pathology [?]. Prediction of amyloid-positive subjects using
MRI-based multivariate methods is an increasing area of
research [?], [?] due to its potential applications in clinical
screening. Studies relating CSF biomarkers and MRI measure-
ments in the literature mostly use standard hypothesis testing
and linear regression techniques. A comparison between CSF
and MRI discriminative and predictive power can be found
in [?] and [?], respectively. In the first, cross-sectional MRI
and CSF measurements are used to predict different clinical
groups along the disease continuum, while in the second
they are used as baseline measurements to predict future
clinical change measured through Clinical Dementia Rating-
sum of boxes (CDR-SB) and MMSE. Both works show
that MRI outperforms CSF but they show complementary
information, providing a boost in performance when using
both for classification and prediction. Finally, the work in [?]
independently relates each CSF measure with brain ROIs using
the General Linear Model and hypothesis testing showing
moderate relationships between baseline CSF measurements
and longitudinal atrophy rates in many brain structures.
II. METHODS
IN this work, we aim at predicting pathological markers(i.e: CSF biomarkers) using brain morphological (i.e. MRI)
features. Our modeling assumptions that there coexist two
main process in the brain (brain aging and AD processes)
that can be described by means of few underlying structures
related to brain morphometry. These latent patterns are further
used to predict AD pathological markers. For this purpose, we
use Partial Least Squares regression (PLSR) methodology [?].
A. PLSR: Partial Least Squares Regression
In general, Partial Least Squares (PLS) is a statistical model
that analyzes the joint variability between two sets of measure-
ments, (X and Y ) on the same observations. Its main goal is to
find latent structures related to both input measurements whose
covariance is maximized. In the same line, the PLSR approach
aims at predicting one set of measurements, Y from the other
X by means of common latent structures that maximize the
joint variability among them. Formally, PLSR finds two sets
of weight vectors (w, c) that jointly decompose the predictor
matrix X ∈ RNxK and the response matrix Y ∈ RNxM into
latent variables (t, u) by maximizing the covariance of the
latent spaces. Here, N stands for the number of observations,
while K and M define the number of predictors and response
variables, respectively.
For a single latent dimension (L = 1) PLSR finds the
underlying representations as linear combinations of input
measurements t = Xw, u = Y c such that
maximize cov(Xw, Y c) = E {(t− t0)(u− u0)} (1)
s.t wTw = 1, cT c = 1
Solving Eq. ?? using Lagrange multipliers, weight vectors
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(2)
For a latent space of dimension L > 1, each sub-
sequent latent factor is computed by iterating over the
same optimization process (i.e. Eq.??,??) and concatenat-
ing the results (W = [w0, w1, ..., wL−1] ∈ RKxL, C =
[c0, c1, ...cL−1] ∈ RMxL, T = [t0, t1, ..., tL−1] ∈ RNxL, U =
[u0, u1, ..., uL−1] ∈ RNxL). However, at each iteration, PLS
uses deflated versions of input measurements (X and Y)
as new predictors and response variables, forcing successive
latent directions to be orthogonal to previous ones and hence,
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maximizing the input variance explained. The deflated version
of X and Y at ith-iteration is:





















with i = 0, ..., L − 2, X0 = X and Y0 = Y Due to
continuous deflation of input spaces, weight matrices (W,C)
do not directly relate input (X,Y ) and latent (T,U ) spaces.
Accounting for that, rotation matrices, Rx,Ry , are defined:
Rx =W · (PT ·W )−1, T = X ·Rx,
Ry = C · (QT · C)−1, U = Y ·Ry (4)
where P = [p0, p1, ..., pL−1] ∈ RKxL, Q =
[q0, q1, ..., qL−1] ∈ RMxL are the so-called loadings.
Finally, PLSR modeling is used for predicting Y from X
using the coefficient matrix B:
Y = TQT + E = XRxQ
T + E
Y = XB + E ,where B = RxQT (5)
where E models the regression error.
B. PLSR orthogonalization and coupling
A common assumption in neuroimaging studies is that the
object of study (e.g: brain morphology) is affected at the same
time by the condition of interest (e.g: AD) and confounding
variables (e.g: age, genetics). The standard solution is to
regress-out the unwanted factors on the condition of interest.
In a PLSR framework, it can be done estimating two separate
models for confounders (MC) and the variable of interest (MI )
and imposing orthogonality between models. Similarly to the
work in [?], we introduce the orthogonality constraint in the
optimization process forcing the associated latent subspace
(TC , TI ) to be orthogonal. The MC model using X,YC as
predictor and response variables, respectively, is found by
solving the regular expression in Eq. ?? for an LC-dimensional
subspace with weights wCi for i = 0 : LC−1. To account for
the variance explained by confounding variables, we subtract
the measurement variance explained by MC in the predictor
variable of MI , resulting in a deflated version of the input
measurement X = X − TCP>C . Hence, the optimization
process for MI model using Yi as response variables is as
follows:
maximize cov(X · w, YI · c) = E
{
(t− t0)> · (u− u0)
}
(6)
s.t wTw = 1, cT c = 1, wT · rCi = 0 ∀= 0, ..., LC − 1
where rCi are the columns of the PLSR rotation matrix RC
of model MC . For an LI -dimensional subspace the resulting
weights can be expressed as:
wj = Xj






rCi ⇒ wj = wj||wj ||
cj = Y
>
Ij · tj ⇒ cj =
cj
||cj || j = 0 : LI − 1 (7)
where Xj and YIj are the deflated version of X0 and YI0
at jth iteration. Finally, the full PLSR model (Mfull, Lfull-
dimensional) is built by concatenating latent scores and ro-
tation matrices from both models: T = concat(tl) and R =
concat(Rl) where l = 0, ..., LC − 1, ..., LC + LI − 1
C. Model definition: Maging, MAD
We define two separate models for brain aging and AD
effects (MC=Maging, MI=MAD). We first estimate Maging
model using normal aging subjects and brain volumetric
features as predictor and age as response variable. Thereafter,
we use the methodology state in section ?? to fit the MAD
model using subjects in the AD pathophysiological path and
a deflated version of brain volumetric features as predictor
and CSF biomarkers (Aβ, p-tau, t-tau) as response variables.
The final latent space (Mfull) is built by concatenating the
latent model associated with brain aging and the latent model
associated with AD markers.
D. Statistical inference
The outcome measures of interest using the aforementioned
PLSR model are: (i) the effect strength ρl(s), defined as
the Pearson correlation of the lth latent factor and a certain
variable of interest s (e.g. CSF biomarkers, age) and (ii) the
effect type, νl defined as the projection from input X-space to




νl = rl l = 0, ..., L
full − 1
(8)
For statistical inference over the outcome measures of
the PLSR model, non-parametric permutation testing is used
[?]. The goal is to find latent patterns that are relevant for
brain condition variables (s). The null hypothesis states that
there is no correlation between lth latent factor of the model
and response variable s and is estimated by breaking the
initial relationship between brain morphology (X) and CSF
biomarkers (Y). It can be done by permuting subject indices on
Y measurements and using this new dataset (X,Yperm) to fit a
PLSR model. The resulting latent space is used to compute the
effect strength for each AD biomarker and age. This procedure
is repeated Nperm times to estimate the sampling distribution
for each variable (s) under the null hypothesis.
III. EXPERIMENTAL ANALYSIS
A. Data
In our experiments we use the publicly available dataset
from the Alzheimer’s Disease Neuroimaging Initiative1. We
1http://adni.loni.usc.edu
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build a sample of N = 802 subjects split into diagnostic
categories following recently published guidelines [?]: NHC =
189 healthy controls (HC), NPC = 136 preclinical (PC)
subjects, NMCI = 330 subjects labeled as mild cognitive im-
pairment (MCI) and NAD−dementia = 147 subjects diagnosed
with dementia due to AD. MCI and AD-dementia subjects are
diagnosed following the standard criteria used in ADNI and
reported in [?] while for PC subjects we select asymptomatic
subjects with positive amyloid-beta using the extensively used
threshold at Aβ < 192 pg/mL [?]. All subjects have a T1-
weighted MRI available, preprocessed using FreeSurfer2 and
segmented according to [?] and [?] into regions of interest
(ROIs). Grey matter volume divided by the total intracranial
volume and cortical thickness averages are computed for
each ROI and used as predictor variables (X). Age and CSF
biomarkers (Aβ, p-tau, t-tau) are used as response variables
(Y). Together with age and CSF biomarkers, a normalized CSF
index as diagnostic metric for disease progression (AD-CSF,
[?]) is also used for the analysis of AD pathological effects
on the latent model. The AD-CSF index is a combination of
CSF biomarkers and has two different forms: (i) AD-CSF1 that
involves p-tau protein and Aβ and (ii) AD-CSF2 that involves
t-tau and Aβ.
We use the linear regression model in Eq. ?? to define
the dimension of each latent space, L, by evaluating the total
mean absolute error (MAE) of the predicted response variables
in a 5-fold cross-validation framework [?]. To model brain
aging, we use only HC subjects and set Laging = 2 while for
modeling brain AD we investigate two a priori hypothesis:
(i) latent patterns (effect-type) governing AD pathology are
linear across all continuum with possibly different effect
strengths at different stages and (ii) latent patterns governing
AD pathology are stage-wise linear across the continuum. For
the first case, we model brain AD with LAD = 4 using PC,
MCI and AD-dementia subjects together in one single model,
while for the second case we model brain AD separately at
each stage resulting in 4 different models for NC, PC, MCI
and AD-dementia subjects (LAD = 4-dimensional model for
each stage). The overall latent space in both cases is built by
concatenating latent factors from the brain aging model (t0, t1)
and from AD model (t2, t3, t4, t5). To refer to subspaces found
using volumetric or cortical thickness data we use tVi and t
CT
i ,
respectively. We investigate the effect strength of each latent
dimension with age and AD pathological markers and assess
their relevance using permutation testing with Nperm = 1000
permutations and an uncorrected threshold of p<0.05. The
associated brain morphometric patterns for aging and AD
processes are shown and compared with the literature. Finally,
we show the predictive power of each model using a 5-fold
cross-validation framework to report the mean absolute error
(MAE) of each variable of interest.
B. Single model for AD pathology
Using a single model for all disease stages, we assume
that the effect type of dementia is preserved throughout the
AD continuum even though the effect strength might change
2https://surfer.nmr.mgh.harvard.edu/
at each stage. The effect strength of brain condition markers
on each latent factor (ρl(s)) is shown in figure ?? and listed
in Tables ??,?? (Appendix ??) with the associated p-values
for models using volumetric and cortical thickness features,
respectively.
To better understand the model of each measurement (vol-
umetric and cortical thickness), we first analyze the effect
strength related to the variables of interest at each latent
dimension ρl(s). In figure ?? we show the absolute value of the
correlation between each latent variable tl and the respective
indicators s = age, CSF biomarkers and the two AD-CSF
indices evaluated separately on subjects at specific AD stages
(HC, PC, MCI, AD-dementia).
(a) Volume
(b) Cortical Thickness
Fig. 1: Absolute value of the effect strength (single model)
on several indicators evaluated at different stages: age (black),
amyloid-beta (red), p-tau (green), t-tau (blue), AD-CSF-1 (ma-
genta), AD-CSF-2 (cyan). Latent variables 0 and 1 correspond
to brain aging model and latent variables 2, 3, 4 and 5
correspond to brain AD and are shown in the x-axis.
Each effect type can be seen as a morphological pattern
responding to certain conditions. According to the results in
Tables ??,?? (Appendix ??) we can distinguish three different
types of relevant (p<0.05) patterns along the AD continuum:
(i) age-related patterns associated with high correlation with
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age, (ii) AD-related patterns that present high correlation with
AD markers and (iii) mixed age and AD-related patterns that
show high correlation values with age and several indicators
of AD progression. The first one is found relevant on normal
aging subjects, while the other two coexists along the AD
continuum, meaning that aging and AD processes might
partially overlap across the brain. We show an example of
each type of pattern for volumetric features in figure ?? and
for cortical thickness features in figure ??, in line with the
corresponding effect strengths at each stage.
In figure ?? we show an age related pattern with high
effect strength at pre-dementia stages (HC, PC and MCI)
but low effect strength at AD-dementia stage. This pattern
is estimated using only HC subjects and Maging model and
shows whole brain atrophy except for the choroid plexus
regions. An AD-related pattern (t2) is depicted in figure ??
showing high correlation with AD pathological markers both
on subjects along the whole AD continuum and independently
at all stages. It shows a highly symmetric pattern were positive
and negative values indicate neurodegeneration and increased
ROI volume, respectively, due to its positive correlation with
CSF-Aβ and negative correlation with CSF-ptau and CSF-ttau
values. Cortical regions (parahippocamapus, middle temporal,
transverse temporal, inferior temporal) and subcortical regions
(hippocampus, amygdala and fusiform) of the temporal lobe as
well as regions such as the choroid plexus and, specially, the
entorhinal cortex are the most affected regions positively cor-
related with t2, indicating neurodegeneration over the course
of AD. Other regions such as the precentral or the pars orbitalis
are negatively correlated with t2. Finally, a mixed age and AD-
related pattern (t3) is shown in figure ??, which is negatively
correlated with age and positively correlated with CSF-ptau,
CSF-ttau and their associated indices along the AD continuum
and independently at each stage while it remains independent
of CSF-Aβ values. Among the regions driving this pattern, we
found choroid plexus, precuneus (negatively correlated with
t3), temporal pole and parahippocampus (positively correlated
with t3) the most relevant ones, indicating that they are
involved in both brain aging and brain AD processes.
Similarly, patterns associated with cortical thickness are
shown in figure ?? and are also split into age-related, AD-
related and mixed age and AD-related effects. Firstly, figure
?? presents an age-related pattern involving overall cortical
reduction with age in the normal aging model Maging except
for the cingulate regions that show increased thickness once
corrected by the total intracranial volume. Secondly, an AD-
related pattern is depicted in figure ??, involving cortical
shrinkage of temporal regions (superior, middle, inferior) and
the entorhinal cortex and increased thickness at regions such
as precentral or transverse temporal. Finally, an age-AD mixed
related pattern with opposite relationship between age (-) and
CSF p-tau/t-tau (+) is shown in figure ??. It is associated
with cortical shrinkage of parietal lobe regions and precuneus
and increased thickness on parahippocampus, precentral, pars
orbitalis, insula and superior temporal on the left hemisphere.
Overall, similar findings are found for cortical thickness and
volumetric data.
Finally, we evaluate the predictive power of the latent
factors found for both age and CSF biomarkers at differ-
ent disease stages. For better comparison, all indicators are
globally standardized using z-score on all subjects (i.e. mean
centered and normalized by variance). Table ?? shows the
mean absolute error (MAE) for each class using cortical
thickness and volumetric features and can be interpreted as
the fraction of error per standard deviation. These results can
be compared with standard linear regression method found in
figures ??,?? (Appendix ??).
Features Diagnosis Age CSF Aβ CSF p-tau CSF t-tau
Volume HC 0.49 1.91 0.74 0.71
PC 0.68 0.46 0.72 0.63
MCI 0.67 0.4 0.7 0.72
AD 0.85 0.37 0.88 0.94
Cortical Th. HC 0.55 1.94 0.7 0.63
PC 0.76 0.48 0.68 0.66
MCI 0.77 0.42 0.69 0.72
AD 0.91 0.38 0.87 0.88
TABLE I: Predictive error of response variables for each
diagnosis label and feature type using a single model for all
AD continuum.
Age is best predicted using HC subject and it increases
with later stages at the AD continuum, showing that features
affected by age are also affected by the disease. CSF Aβ
biomarker presents lower predictive error at AD continuum
stages and high predictive error at HC stage probably due to
the standardization process, where it presents low variance at
AD continuum stages and higher variance at HC stage. CSF
p-tau/t-tau seem not very predictable using brain morphometry
measurements. Compared to standard linear regression, we
found no clear gain of our methodology for the regression task.
Hence, even though encountered patterns are highly related
with certain conditions, they are not predictive of AD markers.
C. Multiple models for AD pathology
Under the assumption that underlying processes governing
brain structure along the AD continuum might differ between
stages, we fit a brain AD model independently for each stage
including (i) HC, (ii) PC, (iii) MCI and (iv) AD-dementia.
Similarly to section ??, we perform the analysis for volumetric
and cortical thickness measurements and show the effect
strength of each brain latent model with respect to several
variables of interest at their corresponding stage (figure ??).
A complete list of all effects strengths with their associated
p-values is listed in Tables ??,?? (Appendix ??)
Underlying patterns from the brain aging model remain the
same while latent factors related to brain AD model increase
their effect strength and statistical relevance at each stage.
More specific patterns of brain AD are found for each AD
stage. Here, we focus on AD-related latent factors found in
previous section (Sec. ??) to discover differences between
brain morphological patterns related to AD at specific stages.
Hence, in figure ?? and figure ?? we show the effect-type of
the third latent dimension using volumetric (tV2 ) and cortical
thickness features (tCT2 ), respectively. Both figures show the
highest correlation with AD pathological markers.
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(a) Age-related pattern corresponding to the first latent dimension of the model tV0
(b) AD-related pattern corresponding to the third latent dimension of the model tV2
(c) Mixed age and AD-related pattern corresponding to the fourth latent dimension of the model tV3
Fig. 2: Examples of relevant latent brain morphological patterns (effect-type) using volumetric features. Values at each ROI
represent their influence to the latent space. The corresponding effect strength of each condition at different stages of the
disease is shown on the right.
Here, we concretely study the third dimension of the
model (t2), an AD-related process that presents the highest
correlation with AD pathological markers with both cortical
thickness and volumetric features. In figure ?? we present the
underlying pattern found at each stage of the disease using
volumetric features. Compared to effect type found in previous
analysis (figure ??), the effect type on MCI and AD-dementia
stages appears to be very similar with the addition of the
pallidum showing compensatory effect in the later. On the
other hand, in the PC stage slightly differs from the global
AD pattern yielding an specific preclinical signature. The
neurodegeneration pattern involve choroid plexus and pallidum
while pericalcarine show increased mean ROI volume. Again,
similar results are found addressing volumetric and cortical
thickness features.
For predictive analysis, all indicators are globally stan-
dardized using z-score on all subjects (i.e. mean centered
and normalized by variance). In Table ?? we summarize the
mean absolute error (MAE) per class that can be interpreted
as the fraction of error per standard deviation. Even though
stage-wise modeling provides a higher effect strength and
more relevant brain AD patterns, the predictive power of
CSF biomarkers is slightly worse for late stages of the AD
continuum, probably indicating a lower generalization power
of the brain features found for the same number of latent
dimensions. Nonetheless, PLSR has higher predictive power
than the standard linear regression using raw morphometric
features (Table ?? from Appendix ??).
IV. DISCUSSION
In this work we aim at predicting AD pathological markers
from brain morphology in elderly adults. To this end, we
disentangle aging and pathological processes by orthogonal
projections in a lower-dimensional subspace describing brain
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(a) Age-related pattern corresponding to the first latent dimension of
the model tCT0
(b) AD-related pattern corresponding to the third latent dimension of
the model tCT2
(c) Mixed age and AD-related pattern corresponding to the third latent
dimension of the model tCT3
Fig. 3: Examples of relevant latent brain morphology patterns
(effect-type) using cortical thickness features.Values at each
ROI represent their influence to the latent space. The corre-
sponding effect strength of each condition at different stages
of the disease is shown on the right.
morphology along the disease continuum. We provide two
different approaches to model the AD continuum: linear and
stage-wise linear models, assuming in the later that brain
anatomy might differ between AD stages. Statistical signif-
icance and predictability capacity of each model is assessed
using either grey-matter volume or cortical thickness measure-
ments as brain morphological features. Joint modeling of both
types of features do not reveal further insights since the overall
effect and predictive power remain similar indicating that they
might not provide sufficient complementary information.
Both linear and stage-wise linear models find relevant
patterns related to age, AD and a mixture of both, meaning that
aging and disease processes might overlap, specially signifi-
cant for later stages of the disease (MCI, AD-dementia). Using
a single model for the whole AD continuum find common
structures that are affected over the course of the disease,
delineating the AD signature supported in the literature [?].
(a) Volume
(b) Cortical Thickness
Fig. 4: Absolute value of the effect strength (multiple models)
on several indicators evaluated at the respective disease stages:
age (black), amyloid-beta (red), p-tau (green), t-tau (blue),
AD-CSF-1 (magenta), AD-CSF-2 (cyan). Latent variables 0
and 1 correspond to brain aging model and latent variables 2,
3, 4 and 5 correspond to stagewise brain AD and are shown
in the x-axis.
On the other hand, fitting a model to each disease stage allow
to find temporally specific patterns and increase the effect
strength of AD pathological markers at each stage. While
a single model find relevant patterns involving typical AD-
related regions in the temporal lobe, using separate stage-
wise linear models allows to uncover significant structures at
specific stages. Using multiple models we could fit a separate
model for each stage along the AD continuum increasing the
correlation between descriptive brain morphological patterns
and AD pathological markers. In detail, we found that brain
structure at MCI and AD-dementia stages relieve morpholog-
ical patterns overlapping with the previously found AD sig-
nature. However, at preclinical (PC) stage the join variability
of CSF biomarkers and brain structure follow a different and
more specific pattern and thus, motivating the separate study
of a preclinical AD signature, as several recent studies point





Fig. 5: AD-related effect-type of the brain latent model using
cortical thickness features. It corresponds to the third latent
dimension of the model tV2 at each stage of the AD continuum.
The effect strength at each disease stage is shown on the top.
out [?], [?]. Interestingly, the pallidum effect over the course of
AD is only detected using stage-wise modelling since it shows
early degeneration but then it remains unaffected by the course
of the disease. Some other structures, such as pericalcarine at
PC stage or pallidum at AD-dementia stage, showed increased
volume/thickness once corrected by age and the intracranial
(a) PC stage (b) MCI stage
(c) AD stage (d) Correlation
Fig. 6: AD-related effect-type of the brain latent model
using cortical thickness features. It corresponds to the third
latent dimension of the model tCT2 at each stage of the AD
continuum. The effect strength at each disease stage is shown
on the bottom-right.
Features Diagnosis Age CSF-Aβ CSF-ptau CSF-ttau
Volume HC 0.49 0.51 0.38 0.34
PC 0.68 0.5 0.75 0.58
MCI 0.67 0.41 0.72 0.75
AD 0.85 0.33 1.07 1.0
Cortical Th. HC 0.55 0.54 0.36 0.36
PC 0.76 0.48 0.73 0.61
MCI 0.77 0.43 0.7 0.77
AD 0.91 0.34 0.98 1.05
TABLE II: Predictive error of response variables for each
diagnosis label and feature type using a separate model for
each AD stage.
volume, which might be interpreted as compensatory effects
due to increasing brain activity at those regions [?], [?].
Moreover, we provide a confounder model orthogonal to the
AD continuum model that attempt to describe the brain aging
process. It is estimated using only healthy control subjects
and presents consistent results with the literature [?], [?], [?]
for both volumetric and cortical thickness features involving
global atrophy and cortical thinning, except for the choroid
plexus region. This pattern appear to be highly correlated pre-
dementia stages (HC, PC, MCI) but has low effect strength
at the dementia stage, providing more evidence of a higher
overlap between aging and disease processes at later stages.
Finally, we assess the predictive power of both models and
compare to standard linear regression model. Using stage-
wise modeling increases the overfitting at each stage, but the
effect is mitigated using PLSR compared to linear regression.
However, using a single model for the whole AD continuum
provides similar results for both methods. Overall, the pre-
dictive performance is moderate to low and depends on the
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disease stage, being worse at later stages (AD-dementia).
Our results highlight the potential of using multivariate
models to better detect and disentangle aging and AD patho-
logical effects on brain structure instead of using univariate
regression models and hypothesis testing studying each brain
region independently [?]. Multivariate models are able to
capture relevant and spatially distributed patterns of structural
changes in the brain. In this work, we identify patterns of
common variability between AD pathology, defined using CSF
biomarkers, and brain structure, defined using either volu-
metric or thickness features. Throughout the literature, many
multivariate approaches define AD pathology with binary or
categorical variables (e.g: clinical diagnosis [?], [?] or amyloid
status [?], [?]) and use machine learning as a multivariate
model. However, the quantization of AD pathology in few
categories reduces the modeling capacity of its variability and
heterogeneity. To account for that, other works use single con-
tinuous clinical scores [?], [?], which is suited for modeling the
later stages of the disease. Instead, CSF biomarkers, as used in
our approach, are shown to better describe the full spectrum of
AD [?]. Another recent multivariate approach to detect brain
changes uses an event-based model [?] that clusters subjects
depending on spatially distributed and temporally aligned brain
changes, being well-suited for e.g. patient staging. However,
they make a set of assumptions such that biomarkers vary
independently and do not make use of underlying AD patho-
logical markers. Instead of finding a sequence of events, in
this work we could identify few underlying patterns of brain
variability that are maximally related to AD pathology finding
three different types of patterns: age-related, AD-related and
mixed age and AD related.
V. CONCLUSIONS
We present a multivariate framework that describes struc-
tural changes related two different processes that may occur
simultaneously in elderly subjects: brain aging and brain AD.
Age and CSF biomarkers describe each process, respectively,
and brain morphological features are used to assess brain struc-
tural information. PLSR is used to find latent spaces related
to each brain condition and we incorporate a orthogonality
constraint between both subspaces. Results show that along the
AD continuum brain patterns related to age, AD and a mixture
of both coexist which might indicate that brain aging and
AD processes partially overlap. As largely investigated in the
literature, we found that temporal lobe changes occur earlier
in the disease continuum and are followed by later changes
in parietal regions. Moreover, some regions of the brain
present compensation effects once brain aging is considered.
AD pathology expresses similarly in volumetric and cortical
thickness features. One limitation of the model is that localized
interpretations of condition effects (e.g. aging, dementia) in
independent ROIs is not possible and the only conclusion that
can be drawn is related to the overall morphometric patterns
found. Future work may involve considering AD comorbidities
and incorporating other imaging modalities in the study.
APPENDIX I
LINEAR REGRESSION FOR PREDICTION
We use linear regression with raw brain morphometric
features as a baseline method for predictive analysis. Linear
regression uses raw features to predict AD pathological mark-
ers and age. Tables ?? and ?? summarize the results using a
single model for the whole AD continuum and a model for
each AD stage, respectively.
Features Diagnosis Age CSF-Aβ CSF-ptau CSF-ttau
Volume HC 0.5 1.91 0.8 0.72
PC 0.69 0.51 0.74 0.71
MCI 0.68 0.43 0.74 0.73
AD 0.85 0.41 0.93 0.89
Cortical Th. HC 0.53 1.89 0.77 0.76
PC 0.72 0.51 0.73 0.78
MCI 0.74 0.43 0.71 0.78
AD 0.88 0.4 0.96 0.99
TABLE III: Predictive error of response variables for each
diagnosis label and feature type using a single linear regression
model for all AD continuum.
Features Diagnosis Age CSF-Aβ CSF-ptau CSF-ttau
Volume HC 0.5 0.67 0.58 0.49
PC 0.69 0.88 1.4 0.86
MCI 0.68 0.47 0.8 0.8
AD 0.85 0.63 1.82 1.7
Cortical Th. HC 0.53 0.67 0.46 0.47
PC 0.72 0.78 1.41 0.96
MCI 0.74 0.46 0.76 0.83
AD 0.88 0.58 1.4 1.35
TABLE IV: Predictive error of response variables for each
diagnosis label and feature type using linear regression fitting
a specific model for each AD stage.
APPENDIX II
STATISTICAL INFERENCE TABLES
We provide numbers of effect-strength and associated p-
value of AD pathological markers and age on the brain
morphological latent model at different AD stages in Ta-
bles ??,??,??,??.
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AD stage Marker Latent dimension
First Second Third Fourth Fifth Sixth
HC
Age -0.44 (0.003) 0.49 (<0.001) 0.01 (0.789) -0.01 (0.89) -0.0 (0.983) 0.0 (0.941)
CSF Aβ -0.01 (0.899) 0.06 (0.311) 0.01 (0.903) 0.14 (0.072) 0.12 (0.205) 0.09 (0.245)
CSF p-tau -0.01 (0.807) -0.01 (0.808) -0.01 (0.894) 0.06 (0.422) 0.06 (0.508) 0.1 (0.216)
CSF t-tau -0.0 (0.996) -0.01 (0.937) -0.19 (0.076) 0.22 (0.016) 0.08 (0.485) 0.09 (0.418)
AD-CSF1 -0.13 (0.197) 0.02 (0.893) 0.02 (0.776) 0.04 (0.601) -0.03 (0.609) -0.04 (0.638)
AD-CSF1 0.05 (0.497) -0.0 (0.976) -0.01 (0.958) 0.04 (0.672) 0.08 (0.539) -0.13 (0.224)
PC
Age -0.42 (0.031) 0.28 (0.465) -0.14 (0.31) -0.19 (0.211) -0.1 (0.462) -0.16 (0.168)
CSF Aβ -0.01 (0.844) -0.07 (0.282) 0.18 (0.064) 0.05 (0.734) 0.11 (0.314) 0.05 (0.572)
CSF p-tau 0.05 (0.61) 0.03 (0.769) -0.31 (0.011) 0.32 (0.003) -0.13 (0.349) -0.04 (0.754)
CSF t-tau 0.07 (0.452) -0.0 (0.999) -0.32 (0.006) 0.35 (<0.001) -0.2 (0.082) 0.02 (0.891)
AD-CSF1 0.02 (0.767) 0.08 (0.238) -0.28 (0.005) 0.15 (0.148) -0.15 (0.202) -0.07 (0.466)
AD-CSF1 0.05 (0.426) 0.01 (0.921) -0.2 (0.015) 0.16 (0.074) -0.26 (0.002) -0.01 (0.836)
MCI
Age -0.36 (0.072) 0.31 (0.196) -0.12 (0.524) -0.38 (<0.001) -0.08 (0.693) -0.05 (0.705)
CSF Aβ 0.12 (0.205) -0.09 (0.427) 0.26 (0.001) 0.01 (0.982) 0.06 (0.693) -0.01 (0.929)
CSF p-tau 0.04 (0.387) -0.05 (0.364) -0.22 (0.006) 0.26 (<0.001) -0.27 (<0.001) -0.19 (0.01)
CSF t-tau 0.04 (0.468) -0.03 (0.616) -0.33 (<0.001) 0.33 (<0.001) -0.21 (0.048) 0.08 (0.394)
AD-CSF1 -0.08 (0.436) -0.04 (0.712) -0.28 (<0.001) 0.17 (0.068) -0.18 (0.065) -0.11 (0.179)
AD-CSF1 -0.05 (0.412) 0.03 (0.623) -0.33 (<0.001) 0.19 (0.069) -0.18 (0.114) 0.05 (0.601)
AD
Age -0.15 (0.25) 0.26 (0.092) 0.26 (0.181) -0.48 (<0.001) -0.32 (0.122) 0.01 (0.96)
CSF Aβ -0.15 (0.38) -0.1 (0.576) 0.02 (0.771) 0.0 (0.977) -0.09 (0.294) -0.03 (0.725)
CSF p-tau 0.12 (0.336) 0.05 (0.769) -0.25 (0.003) 0.25 (0.004) -0.24 (0.003) -0.12 (0.164)
CSF t-tau 0.12 (0.229) -0.09 (0.399) -0.28 (0.003) 0.37 (<0.001) -0.15 (0.191) 0.17 (0.093)
AD-CSF1 0.18 (0.336) 0.12 (0.576) -0.09 (0.213) 0.23 (<0.001) -0.26 (<0.001) -0.07 (0.386)
AD-CSF1 0.15 (0.238) -0.06 (0.717) -0.11 (0.304) 0.3 (0.002) -0.16 (0.104) 0.09 (0.384)
AD continuum
Age -0.31 (0.079) 0.29 (0.136) -0.03 (0.82) -0.37 (<0.001) -0.15 (0.312) -0.07 (0.544)
CSF Aβ 0.15 (0.189) -0.12 (0.385) 0.33 (<0.001) 0.02 (0.958) 0.04 (0.893) 0.0 (0.976)
CSF p-tau -0.05 (0.43) 0.03 (0.723) -0.35 (<0.001) 0.25 (0.001) -0.22 (0.058) -0.14 (0.153)
CSF t-tau -0.09 (0.431) 0.01 (0.94) -0.45 (<0.001) 0.31 (0.005) -0.18 (0.314) 0.08 (0.518)
AD-CSF1 -0.12 (0.243) 0.06 (0.679) -0.35 (<0.001) 0.17 (0.351) -0.19 (0.175) -0.1 (0.335)
AD-CSF1 -0.15 (0.246) 0.06 (0.709) -0.43 (<0.001) 0.18 (0.517) -0.18 (0.326) 0.03 (0.804)
TABLE V: Volume effect-strength (p-value) on each associated marker of interest separated by AD stages using a single PLS
model for AD pathology.
AD stage Marker Latent dimension
First Second Third Fourth Fifth Sixth
HC
Age -0.42 (0.026) 0.45 (0.011) -0.03 (0.85) -0.18 (0.033) -0.03 (0.752) -0.1 (0.216)
CSF Aβ 0.03 (0.739) 0.07 (0.335) 0.04 (0.611) 0.1 (0.24) 0.02 (0.849) -0.13 (0.06)
CSF p-tau -0.01 (0.864) 0.01 (0.865) 0.09 (0.308) 0.02 (0.795) -0.05 (0.512) 0.11 (0.252)
CSF t-tau 0.03 (0.892) 0.19 (0.064) -0.08 (0.292) 0.1 (0.179) -0.01 (0.941) 0.08 (0.414)
AD-CSF1 -0.13 (0.16) 0.15 (0.114) 0.22 (0.005) -0.07 (0.493) 0.01 (0.927) 0.09 (0.217)
AD-CSF1 0.11 (0.267) -0.0 (0.98) -0.03 (0.754) 0.18 (0.015) 0.16 (0.03) 0.06 (0.561)
PC
Age -0.4 (0.055) 0.15 (0.676) -0.33 (0.147) -0.2 (0.588) -0.07 (0.668) -0.05 (0.701)
CSF Aβ 0.02 (0.672) -0.14 (0.087) 0.14 (0.157) -0.06 (0.492) 0.13 (0.318) -0.01 (0.937)
CSF p-tau -0.13 (0.2) 0.18 (0.166) -0.35 (0.011) 0.34 (0.003) -0.06 (0.8) -0.02 (0.923)
CSF t-tau -0.11 (0.254) 0.18 (0.162) -0.35 (0.011) 0.35 (<0.001) 0.07 (0.732) 0.17 (0.268)
AD-CSF1 -0.14 (0.174) 0.14 (0.304) -0.34 (0.008) 0.17 (0.245) -0.13 (0.55) 0.05 (0.742)
AD-CSF1 -0.04 (0.46) 0.14 (0.151) -0.24 (0.025) 0.17 (0.095) -0.01 (0.977) 0.22 (0.059)
MCI
Age -0.41 (0.026) 0.13 (0.723) -0.19 (0.551) -0.36 (0.03) 0.04 (0.815) -0.08 (0.394)
CSF Aβ 0.15 (0.063) -0.06 (0.584) 0.12 (0.095) -0.0 (0.988) 0.02 (0.749) 0.24 (<0.001)
CSF p-tau -0.02 (0.551) -0.01 (0.894) -0.21 (0.006) 0.27 (<0.001) 0.22 (0.009) -0.08 (0.422)
CSF t-tau -0.11 (0.184) 0.08 (0.401) -0.26 (0.001) 0.3 (<0.001) 0.3 (<0.001) -0.07 (0.455)
AD-CSF1 -0.14 (0.129) 0.02 (0.858) -0.23 (<0.001) 0.15 (0.065) 0.09 (0.435) -0.11 (0.152)
AD-CSF1 -0.17 (0.102) 0.1 (0.433) -0.25 (0.002) 0.21 (0.009) 0.14 (0.193) -0.1 (0.244)
AD
Age -0.06 (0.5) 0.17 (0.318) 0.19 (0.556) -0.6 (<0.001) 0.21 (0.568) 0.01 (0.942)
CSF Aβ -0.12 (0.49) -0.08 (0.482) -0.06 (0.508) -0.06 (0.508) 0.03 (0.733) 0.19 (0.01)
CSF p-tau -0.06 (0.541) -0.05 (0.555) -0.25 (0.004) 0.21 (0.022) 0.2 (0.066) -0.2 (0.017)
CSF t-tau -0.15 (0.533) -0.13 (0.31) -0.24 (0.003) 0.27 (0.002) 0.19 (0.112) 0.06 (0.569)
AD-CSF1 0.0 (0.911) -0.08 (0.182) -0.11 (0.075) 0.15 (0.017) 0.12 (0.133) -0.18 (0.016)
AD-CSF1 0.03 (0.422) -0.09 (0.181) -0.07 (0.551) 0.25 (<0.001) 0.13 (0.255) -0.02 (0.88)
AD continuum
Age -0.31 (0.053) 0.15 (0.609) -0.11 (0.723) -0.4 (<0.001) 0.07 (0.733) -0.04 (0.667)
CSF Aβ 0.18 (0.068) -0.08 (0.644) 0.25 (0.003) -0.03 (0.924) 0.02 (0.883) 0.21 (<0.001)
CSF p-tau -0.17 (0.187) 0.02 (0.912) -0.35 (<0.001) 0.25 (0.016) 0.17 (0.316) -0.14 (0.174)
CSF t-tau -0.25 (0.136) 0.03 (0.912) -0.42 (<0.001) 0.28 (0.046) 0.23 (0.161) -0.05 (0.692)
AD-CSF1 -0.22 (0.117) 0.03 (0.904) -0.35 (<0.001) 0.15 (0.511) 0.07 (0.716) -0.13 (0.145)
AD-CSF1 -0.24 (0.099) 0.07 (0.794) -0.39 (<0.001) 0.19 (0.356) 0.13 (0.507) -0.07 (0.499)
TABLE VI: Cortical thickness effect-strength (p-value) on each associated marker of interest separated by AD stages using a
single PLS model for AD pathology.
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AD stage Marker Latent dimension
First Second Third Fourth Fifth Sixth
HC
Age -0.44 (0.01) 0.49 (<0.001) -0.07 (0.22) -0.01 (0.88) -0.14 (0.01) 0.1 (0.06)
CSF Aβ -0.01 (0.9) 0.06 (0.29) -0.32 (<0.001) 0.36 (<0.001) -0.23 (<0.001) -0.05 (0.59)
CSF p-tau -0.01 (0.81) -0.01 (0.8) -0.27 (<0.001) -0.22 (<0.001) -0.24 (<0.001) -0.25 (<0.001)
CSF t-tau -0.0 (0.99) -0.01 (0.93) -0.52 (<0.001) -0.2 (0.07) -0.28 (<0.001) 0.28 (<0.001)
AD-CSF1 -0.13 (0.2) 0.02 (0.88) 0.01 (0.87) -0.08 (0.29) -0.09 (0.19) -0.16 (0.02)
AD-CSF1 0.05 (0.5) -0.0 (0.98) -0.16 (0.13) -0.23 (0.02) 0.07 (0.55) 0.14 (0.21)
PC
Age -0.42 (0.04) 0.28 (0.45) 0.1 (0.5) 0.12 (0.44) -0.15 (0.28) 0.25 (0.04)
CSF Aβ -0.01 (0.85) -0.07 (0.28) -0.18 (0.04) -0.06 (0.61) 0.33 (<0.001) -0.19 (0.03)
CSF p-tau 0.05 (0.61) 0.03 (0.8) 0.6 (<0.001) 0.35 (<0.001) -0.22 (0.08) -0.22 (0.09)
CSF t-tau 0.07 (0.48) -0.0 (1.0) 0.58 (<0.001) 0.43 (<0.001) -0.21 (0.1) -0.18 (0.14)
AD-CSF1 0.02 (0.79) 0.08 (0.26) 0.39 (<0.001) 0.28 (<0.001) -0.29 (<0.001) 0.03 (0.8)
AD-CSF1 0.05 (0.47) 0.01 (0.92) 0.33 (<0.001) 0.25 (0.01) -0.27 (<0.001) 0.02 (0.82)
MCI
Age -0.36 (0.07) 0.31 (0.18) 0.02 (0.94) 0.37 (<0.001) 0.08 (0.61) 0.1 (0.52)
CSF Aβ 0.12 (0.21) -0.09 (0.4) 0.25 (0.01) -0.09 (0.6) -0.15 (0.14) 0.01 (0.94)
CSF p-tau 0.04 (0.39) -0.05 (0.36) -0.37 (<0.001) -0.27 (<0.001) 0.11 (0.16) 0.27 (<0.001)
CSF t-tau 0.04 (0.5) -0.03 (0.64) -0.47 (<0.001) -0.28 (<0.001) 0.24 (<0.001) 0.03 (0.75)
AD-CSF1 -0.08 (0.43) -0.04 (0.73) -0.36 (<0.001) -0.11 (0.31) 0.11 (0.23) 0.15 (0.08)
AD-CSF1 -0.05 (0.44) 0.03 (0.61) -0.4 (<0.001) -0.12 (0.27) 0.21 (0.01) 0.07 (0.48)
AD
Age -0.15 (0.27) 0.26 (0.08) 0.48 (<0.001) -0.07 (0.73) -0.22 (0.27) -0.21 (0.28)
CSF Aβ -0.15 (0.36) -0.1 (0.62) -0.02 (0.81) -0.04 (0.59) -0.11 (0.23) 0.02 (0.85)
CSF p-tau 0.12 (0.32) 0.05 (0.79) -0.41 (<0.001) -0.31 (<0.001) -0.32 (<0.001) 0.07 (0.4)
CSF t-tau 0.12 (0.23) -0.09 (0.42) -0.49 (<0.001) -0.32 (<0.001) 0.09 (0.4) -0.27 (<0.001)
AD-CSF1 0.18 (0.34) 0.12 (0.58) -0.25 (<0.001) -0.25 (<0.001) -0.17 (0.02) 0.06 (0.41)
AD-CSF1 0.15 (0.25) -0.06 (0.73) -0.33 (<0.001) -0.24 (0.02) 0.09 (0.34) -0.2 (0.05)
TABLE VII: Volume effect-strength (p-value) on each associated marker of interest separated by AD stages using multiple PLS
models for AD pathology.
AD stage Marker Latent dimension
First Second Third Fourth Fifth Sixth
HC
Age -0.42 (0.02) 0.45 (0.01) -0.05 (0.64) -0.09 (0.43) -0.13 (0.14) -0.16 (0.06)
CSF Aβ 0.03 (0.74) 0.07 (0.33) 0.17 (0.01) -0.37 (<0.001) 0.31 (<0.001) -0.09 (0.23)
CSF p-tau -0.01 (0.83) 0.01 (0.84) 0.42 (<0.001) -0.1 (0.33) -0.18 (0.04) -0.22 (0.01)
CSF t-tau 0.03 (0.88) 0.19 (0.06) 0.44 (<0.001) -0.28 (<0.001) -0.19 (0.02) 0.2 (0.02)
AD-CSF1 -0.13 (0.14) 0.15 (0.12) 0.11 (0.22) 0.13 (0.14) -0.06 (0.45) -0.12 (0.12)
AD-CSF1 0.11 (0.28) -0.0 (0.98) 0.16 (0.05) -0.05 (0.63) 0.02 (0.8) 0.14 (0.09)
PC
Age -0.4 (0.06) 0.15 (0.65) 0.22 (0.39) 0.15 (0.81) -0.24 (0.26) -0.07 (0.66)
CSF Aβ 0.02 (0.67) -0.14 (0.08) -0.24 (0.02) -0.01 (0.89) -0.0 (0.98) -0.33 (<0.001)
CSF p-tau -0.13 (0.17) 0.18 (0.16) 0.56 (<0.001) -0.26 (0.03) -0.23 (0.2) 0.2 (0.23)
CSF t-tau -0.11 (0.23) 0.18 (0.17) 0.52 (<0.001) -0.25 (0.03) -0.25 (0.11) -0.05 (0.76)
AD-CSF1 -0.14 (0.19) 0.14 (0.31) 0.49 (<0.001) -0.05 (0.87) -0.14 (0.51) 0.27 (0.05)
AD-CSF1 -0.04 (0.44) 0.14 (0.16) 0.35 (<0.001) -0.1 (0.37) -0.16 (0.23) 0.12 (0.39)
MCI
Age -0.41 (0.03) 0.13 (0.7) 0.04 (0.91) -0.3 (0.28) -0.3 (0.07) 0.01 (0.88)
CSF Aβ 0.15 (0.07) -0.06 (0.57) 0.08 (0.31) 0.05 (0.54) 0.17 (<0.001) -0.36 (<0.001)
CSF p-tau -0.02 (0.56) -0.01 (0.91) -0.42 (<0.001) 0.2 (<0.001) -0.18 (0.02) 0.05 (0.57)
CSF t-tau -0.11 (0.19) 0.08 (0.41) -0.45 (<0.001) 0.19 (<0.001) -0.22 (0.01) 0.12 (0.2)
AD-CSF1 -0.14 (0.14) 0.02 (0.86) -0.3 (<0.001) 0.03 (0.77) -0.16 (0.05) 0.21 (<0.001)
AD-CSF1 -0.17 (0.1) 0.1 (0.45) -0.34 (<0.001) 0.06 (0.4) -0.18 (0.05) 0.24 (<0.001)
AD
Age -0.06 (0.49) 0.17 (0.32) 0.49 (0.02) -0.07 (0.94) 0.08 (0.78) -0.33 (0.06)
CSF Aβ -0.12 (0.5) -0.08 (0.5) -0.06 (0.53) -0.09 (0.34) 0.05 (0.55) -0.03 (0.66)
CSF p-tau -0.06 (0.58) -0.05 (0.52) -0.39 (<0.001) -0.3 (<0.001) -0.25 (0.01) -0.17 (0.06)
CSF t-tau -0.15 (0.57) -0.13 (0.31) -0.4 (<0.001) -0.35 (<0.001) -0.03 (0.78) 0.18 (0.08)
AD-CSF1 0.0 (0.91) -0.08 (0.2) -0.24 (<0.001) -0.17 (0.01) -0.26 (<0.001) -0.13 (0.08)
AD-CSF1 0.03 (0.4) -0.09 (0.17) -0.25 (<0.001) -0.33 (<0.001) -0.08 (0.4) 0.2 (0.01)
TABLE VIII: Cortical thickness effect-strength (p-value) on each associated marker of interest separated by AD stages using
multiple PLS models for AD pathology.
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